Teva Pharmaceutical Industries Ltd (TEVJF) Cash from Investing Activities (2009 - 2026)

Teva Pharmaceutical Industries (TEVJF) has 18 years of Cash from Investing Activities data on file, last reported at -$491.0 million in Q2 2026.

• Quarterly Cash from Investing Activities fell 308.05% year-over-year to -$491.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $38.0 million (down 95.81% YoY) and the FY2025 annual result came in at $737.0 million, down 6.94% from the prior year.
• Cash from Investing Activities declined to -$491.0 million in Q2 2026, from $229.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $302.0 million in Q2 2023 to a low of -$491.0 million in Q2 2026.
• A 5-year average of $160.6 million and a median of $180.0 million in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities soared 79.17% — and 2026, when it slumped 308.05%.
• Tracing TEVJF's Cash from Investing Activities over 5 years: stood at $168.0 million in 2022, then soared by 79.17% to $301.0 million in 2023, then tumbled by 32.89% to $202.0 million in 2024, then decreased by 18.32% to $165.0 million in 2025, then sank by 397.58% to -$491.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$491.0 million (Q2 2026), $229.0 million (Q1 2026), and $165.0 million (Q4 2025), per Business Quant data.